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Abstract
Rationale Prefrontal cortical dysfunctions, including an
impaired ability to shift perceptual attentional set, are core
features of schizophrenia. Nevertheless, the effectiveness of
second-generation antipsychotic drugs in treating specific
prefrontal dysfunctions remains equivocal.
Objectives To model schizophrenia-like cognitive inflexi-
bility in rats, we evaluated the effects of repeated
administration of ketamine, the noncompetitive antagonist
of the N-methyl-D-aspartate receptor, after a washout period
of 14 days in the attentional set-shifting task (ASST). Next,
we investigated whether the atypical antipsychotics quetia-
pine and sertindole would alleviate the ketamine-induced
set-shifting impairment.
Methods Ketamine (30 mg/kg) was administered intra-
peritoneally to rats once daily for 5 or 10 consecutive days
to assess its efficacy in producing cognitive impairment.
The ASST was performed 14 days following the final drug
administration. Quetiapine (0.63, 1.25 or 2.5 mg/kg) or
sertindole (2.5 mg/kg) was administered per os 120 min
before testing.
Results The results of the present study demonstrate that
ketamine treatment for 10 but not 5 days significantly and
specifically impaired rats’ performance in the extra-
dimensional shift (EDs) stage of the ASST. This cognitive
inflexibility was reversed by acute administration of
sertindole or quetiapine. Quetiapine also promoted set-
shifting in cognitively unimpaired control animals.
Conclusion The data presented here show that subchronic
administration of ketamine induces cognitive inflexibility
after a washout period. This cognitive deficit likely reflects
clinically relevant aspects of cognitive dysfunction encoun-
tered in schizophrenic patients. The beneficial effects of
quetiapine on set-shifting may have therapeutic implica-
tions for the treatment of schizophrenia and other disorders
associated with frontal-dependent cognitive impairments.
Keywords Cognitive flexibility.Attentional set-shifting.
Ketamine.Quetiapine.Sertindole.Schizophrenia.Animal
models.Prefrontal cortex
Introduction
Deficits of prefrontal cortical function are prominent
features of schizophrenia. These neurocognitive dysfunc-
tions include reduced flexibility in modifying behavior in
response to the altering relevance of stimuli. This aspect of
executive function is commonly assessed in humans using
the Wisconsin Card Sorting Test (WCST) (Grant and Berg
1948) and its modified version, the Intradimensional/
Extradimensional Shift (ID/ED) task, developed by Roberts
et al. (1988). In fact, a poor WCST and/or ID/ED
performance, which is an impairment reminiscent of that
observed in patients with frontal lobe damage (Pantelis et
al. 1999), is the key cognitive symptom of schizophrenia
(Elliott et al. 1998).
Cognitive flexibility may also be assessed in the rodent
version of the ID/ED task, i.e., in the attentional set-shifting
task (ASST) (Birrell and Brown 2000). In this paradigm,
rats must select a bowl containing a food reward based on
the ability to discriminate the odors and the media covering
the bait. The ASST requires rats to initially learn a rule and
form an attentional “set” within the same stimulus
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must switch their attention to a new, previously irrelevant
stimulus dimension and, for example, discriminate between
the odors and no longer between the media covering the
bait. The EDs phase, regarded as an index of cognitive
flexibility, is impaired by lesions of the medial prefrontal
cortex (mPFC) (Birrell and Brown 2000). Hence, the ASST
measures specific frontal-dependent cognitive functions in a
way homologous to human tests and therefore represents a
useful translational approach from animal models to the
clinic (Keeler and Robbins 2011).
Noncompetitive antagonists of the N-methyl-D-aspartate
receptor (NMDAR), such as ketamine and phencyclidine
(PCP), produce a behavioral syndrome in healthy humans
that closely resembles the symptoms of schizophrenia
(Lahti et al. 1999). Therefore, NMDAR-based models are
commonly used to mimic a schizophrenia-like state in
laboratory animals. Interestingly, ketamine administration to
healthy volunteers produced inflexible responding in the
WCST, as revealed by an increase in perseverative errors
(Krystal et al. 1994). In line with clinical findings, our
previous study demonstrated that acute administration of
ketamine to rats also impaired their cognitive flexibility
during the EDs phase of the ASST (Nikiforuk et al. 2010).
However, although acute administration of NMDAR
antagonists evokes a broad range of schizophrenia-like
symptoms, experimental data suggest that repeated dosing
protocols might represent a more appropriate preclinical
approach for modeling neurochemical changes relevant to the
pathophysiology of this disorder. Specifically, the repetitive
administrationofNMDAR antagonists reducedtheexpression
of glutamic acid decarboxylase 67 (GAD67) and the calcium-
binding protein, parvalbumin, in cortical aminobutyric acid-
ergic (GABAergic) interneurons (Abdul-Monim et al. 2007).
This GABAergic impairment has been regarded as the most
consistently demonstrated pathological disturbance in schizo-
phrenia (Lewis and Gonzalez-Burgos 2008). Repeated PCP
treatment also evoked a metabolic abnormality, i.e., reduced
glucose utilization in the rat PFC, that resembled the
hypofrontality commonly observed in schizophrenic patients
(Dawson et al. 2010). Additionally, repeated NMDAR
antagonist administration leads to dysfunction of cortical
dopaminergic transmission in both nonhuman primates and
rodents (Jentsch et al. 1997; Jentsch et al. 1998). Because
these enduring neurochemical and metabolic alternations in
the PFC are thought to underlie cognitive impairments
(Dawson et al. 2010; Abdul-Monim et al. 2007; Jentsch et
al. 1997), NMDAR antagonist-based preclinical models may
represent a useful tool for assessing the pro-cognitive efficacy
of antipsychotic drugs.
The first aim of the present study was to investigate the
impact of subchronic (5 or 10 consecutive days) adminis-
tration of the subanesthetic dose (30 mg/kg) of ketamine on
rats' ASST performance assessed after 2 weeks of drug
withdrawal. This protocol has been effective for inducing
behavioral changes mimicking the positive and negative
symptoms of schizophrenia, as revealed by potentiating
dizocilpine-induced hyperlocomotion and by the decrease
in social behavior, respectively (Becker et al. 2003).
Likewise, cognitive deficits were observed in tasks assess-
ing spatial working memory (Enomoto and Floresco 2009)
and reversal learning (Floresco et al. 2009). Additionally,
second-generation antipsychotic drugs (i.e., clozapine and
risperidone) but not typical neuroleptics such as haloperidol
ameliorated ketamine-induced impairment of social inter-
action, suggesting predictive validity of this subchronic
treatment paradigm (Becker and Grecksch 2004). In line
with persistent behavioral abnormalities, this ketamine
dosing schedule also induced dysfunction in GABAergic
interneurons (Keilhoff et al. 2004). Therefore, repeated
ketamine administration represents a validated model in
preclinical schizophrenia research.
Although atypical antipsychotic medications appear to
demonstrate a promising effect on cognitive functioning in
schizophrenia patients (Harvey and Keefe 2001), several
specific dysfunctions including cognitive inflexibility are
not normalized by these treatments (Goldberg et al. 2007).
Accordingly, atypical antipsychotics including clozapine,
olanzapine and risperidone were largely ineffective in
normalizing set-shifting deficits in preclinical schizophrenia
models (Rodefer et al. 2008; Goetghebeur and Dias 2009;
but see also McLean et al. 2008). To date, only sertindole
has consistently been shown to reverse cognitive inflexi-
bility (Broberg et al. 2009; Goetghebeur and Dias 2009;
Kos et al. 2011; Nikiforuk et al. 2010; Rodefer et al. 2008).
Clinical data indicate that among the newer atypical drugs,
quetiapine may possess a distinctive cognitive-enhancing
action (Riedel et al. 2010). The pro-cognitive efficacy of
quetiapine has been demonstrated in several cognitive
domains known to be affected in schizophrenia, including
executive functions (Kopala et al. 2006; Purdon et al. 2001;
Voruganti et al. 2007). Therefore, the second goal of the
present study was to evaluate the effects of quetiapine on the
ASST performance of ketamine-treated and control rats;
sertindole was used as a positive control.
Materials and methods
Animals
Male Sprague–Dawley rats (Charles River, Germany)
weighing 250–280 g on arrival were used in this study.
They were initially group-housed (5 rats/cage) in a
temperature- (21±1°C) and humidity-controlled (40–50%)
colony room under a 12/12-h light/dark cycle (lights on at
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7 days before the start of the experimental procedure. For
1 week prior to testing, rats were individually housed with
mild food restriction (15 g of food pellets per day) and ad
libitum access to water. Behavioral testing was performed
during the light phase of the light/dark cycle. The experi-
ments were conducted in accordance with the NIH Guide
for the Care and Use of Laboratory Animals and were
approved by the Ethics Committee for Animal Experiments,
Institute of Pharmacology.
Attentional set-shifting: apparatus
Testing was conducted in a modified wire rat housing cage
(length×width×height: 42×32×22 cm) with a white plywood
wall dividing half of the length of the cage into two sections
(Nikiforuk et al. 2010). During testing, one ceramic digging
pot (an internal diameter of 10.5 cm and a depth of 4 cm) was
placed in each section. Each pot was defined by a pair of cues
along with two stimulus dimensions. To mark each pot with a
distinct odor, 5 μl of a flavoring essence (Dr. Oetker®, Poland)
was applied on a piece of blotting paper fixed to the external
rim of the pot immediately prior to use. A different pot was
used for each combination of digging medium and odor; only
one odor was ever applied to a given pot. The bait (one-third
of a Honey Nut Cheerio, Nestle®) was placed at the bottom of
the “positive” pot and buried in the digging medium.
Attentional set-shifting: procedure
The procedure was adapted from Birrell and Brown (Birrell
and Brown 2000) and entailed 3 days for each rat.
Day 1, habituation: rats were habituated to the testing area
and trained todig inthepots filled withsawdusttoretrievethe
food reward. Rats were transported from the housing facility
to the testing room where they were presented with one
unscented pot (filled with several pieces of Cheerios) in their
home cages. After the rats had eaten the Cheerio from the
home cage pot, they were placed in the apparatus and given
three trials to retrieve the reward from both of the sawdust-
filled baited pots. With each exposure, the bait was covered
with an increasing amount of sawdust.
Day 2, training: rats were trained on a series of simple
discriminations (SD) to a criterion of six consecutive correct
trials. For these trials, rats had to learn to associate the food
reward with an odor cue (e.g., arrack vs. orange, both pots
filled with sawdust) and/or a digging medium (e.g., plastic
balls vs. pebbles, no odor). All rats were trained using the
same pairs of stimuli. The positive and negative cues for each
rat were presented randomly and equally. These training
stimuli were not used again in later testing trials.
Day 3, testing: rats performed a series of discriminations
in a single test session. The first four trials at the beginning
of each discrimination phase were a discovery period (not
included in the six criterion trials). In subsequent trials, an
incorrect choice was recorded as an error. Digging was
defined as any distinct displacement of the digging media
with either the paw or the nose; the rat could investigate a
digging pot by sniffing or touching without displacing
material. Testing was continued at each phase until the rat
reached the criterion of six consecutive correct trials, after
which testing proceeded to the next phase.
In the simple discrimination (SD) involving only one
stimulus dimension, the pots differed along one of two
dimensions (i.e., a digging medium). For the compound
discrimination (CD), the second (irrelevant) dimension (i.e.,
an odor) was introduced, but the correct and incorrect
exemplars of the relevant dimension remained constant. For
the reversal of this discrimination (Rev 1), the exemplars and
relevant dimension were unchanged, but the previously
correct exemplar was now incorrect and vice versa. The
intradimensional (ID) shift was then presented, comprising
new exemplars ofboththe relevantand irrelevantdimensions,
with the relevant dimension remaining the same previously.
The ID discrimination was then reversed (Rev 2) so that the
formerly positive exemplar became the negative one. For the
extra-dimensional (ED) shift, a new pair of exemplars was
again introduced, but this time a relevant dimension was also
changed.Finally, thelastphase was the reversal(Rev3)ofthe
ED discrimination problem. The exemplars were always
presented in pairs and varied so that only one animal within
each treatment group received the same combination. The
following pairs of exemplars were used: pair 1: odor: lemon
vs. almond, medium: cotton wool vs. crumpled tissue; pair 2:
odor: spicy vs. vanilla, medium: metallic filler vs. shredded
paper; and pair 3: odor: rum vs. cream, medium: clay pellets
vs. silk. Our previous study demonstrated that there were no
differences in performance of rats shifted from odor to
medium and from medium to odor (Nikiforuk et al. 2010).
Therefore, in an attempt to simplify the experimental design,
the order of discrimination was always the same (i.e., from
digging medium to odor). The assignment of each exemplar
in a pair as being positive or negative at a given phase and
the left–right positioning of the pots in the test apparatus on
each trial were randomized.
Drugs
Ketamine (aqueous solution (115.34 mg/ml), Biowet,
Pulawy, Poland) was diluted in sterile physiological saline.
Sertindole (Sigma Aldrich, Poznan, Poland) was dissolved
in a minimum amount of 0.1-M hydrochloric acid and
diluted with saline, and quetiapine (AstraZeneca) was
suspended in 0.5% methylcellulose.
Ketamine (30 mg/kg) was administered intraperitoneally
to rats once daily for 5 or 10 consecutive days. The ASST
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tration. Animals were left undisturbed during the washout
period except for the last 2–3 days when habituation and
training were performed. Control animals received vehicle
(physiological saline) according to the same experimental
schedule. Because no differences were observed between
animals receiving vehicle injections for 5 or 10 days, these
subgroups were collapsed into one vehicle-treated group for
further statistical analysis (Fig. 1).
Sertindole and quetiapine were given per os (PO)
120 min before testing. Drugs or physiological saline were
administered in a volume of 1 ml/kg of body weight.
The ketamine treatment regime and doses of antipsy-
chotics (i.e., sertindole and quetiapine) were based on
previously reported studies (Nikiforuk et al. 2010; Becker
et al. 2003; Swerdlow et al. 1996).
Data analysis
The number of trials required to achieve the criterion of six
consecutive correct responses was recorded for each rat and
for each discrimination phase. Additionally, the time
required by the rats to complete all discriminations was
recorded because the compounds could nonspecifically
affect performance. The effect of ketamine administration
was assessed using two-way ANOVAs with ketamine
treatment (0, 5 and 10 days) as a between-subject factor
and discrimination phase (SD, CD, Rev 1, ID, etc.) as a
within-subject factor. Data from experiments evaluating the
effects of antipsychotic drugs were calculated using three-
way ANOVAs with one within-subject factor, i.e., discrim-
ination phase, and two between-subject factors: ketamine
treatment (0 and 10 days) and a respective antipsychotic
drug treatment (sertindole: 0 and 2.5 mg/kg, or quetiapine:
0, 0.63, 1.25 and 2.5 mg/kg). Post-hoc comparisons were
performed using the Newman–Keuls test. The alpha value
was set at p<0.05. The data fulfilled the criteria for normal
distribution. Statistical analyses were performed with the
use of Statistica 7.0 for Windows.
Results
Effect of repeated ketamine administration on rats’
performance on the attentional set-shifting task
As illustrated in Fig. 1, there was a statistically significant
interaction between ketamine treatment and the discrimina-
tion phase: two-way ANOVA interaction factor F(12, 126)=
18.26, P<0.0001. Post-hoc analysis revealed that vehicle-
treated rats required significantly more trials to reach the
criterion on the ED than the ID stage of the task, indicating
that they had formed an attentional set towards the relevant
dimension before the ED discrimination stage. Furthermore,
repeated ketamine administration (30 mg/kg) for 10 (but not
5) consecutive days significantly and specifically impaired
rats’ performance in the ED stage of the ASST, as indicated
by an increased number of trials to criterion during this
phase. There was no significant drug effect during any other
discrimination stage.
Corresponding to the increased number of trials during the
ED phase, 10-day ketamine administration also prolonged the
time to complete this discrimination stage (vehicle: 13.5±
0.9 min and ketamine×10 days: 26.3±0.9; ANOVA interac-
tion: F(12, 126)=9.71, P<0.0001; data not shown).
Effect of sertindole on the set-shifting ability
of vehicle- and ketamine-treated rats
As illustrated in Fig. 2, there was a statistically significant
interaction between ketamine treatment, sertindole treat-
ment and discrimination phase: three-way ANOVA interac-
tion factor F(6,120)=3.73, P<0.05. Acute administration of
sertindole (2.5 mg/kg, PO) reversed the 10-day ketamine-
administration-induced deficit in ED set-shifting perfor-
mance. In addition, sertindole administration to vehicle-
treated controls did not produce differences across any of
the discrimination phases.
The sertindole-induced facilitation of EDs performance
in ketamine-treated rats was associated with reduced time to
complete this phase (ketamine–vehicle: 21.3±1.2 min and
ketamine–sertindole: 13.0±1.6 min; ANOVA interaction: F
(6,120)=2.43, P<0.05; data not shown).
Fig. 1 Enduring debilitating effects of repeated ketamine administra-
tion on the performance of the attentional set-shifting task in rats.
Ketamine was administered for 5 or 10 consecutive days, and the test
was performed 14 days following the last injection. The results
represent the mean ± S.E.M. number of trials required to reach the
criterion of six consecutive correct trials for each of the discrimination
phases (N=8 rats per group).
+++ p<0.001 vs. vehicle-treated group’s
IDs performance, *** p<0.001 vs. the vehicle-treated group’s EDs
performance
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As illustrated in Fig. 3, there was a statistically significant
interaction between the ketamine treatment, quetiapine
treatment and discrimination phase: three-way ANOVA
interaction factor F(18,318)=1.79, P<0.05. Acute admin-
istration of quetiapine (1.25 and 2.5 mg/kg, PO) reversed
the subchronic ketamine-induced deficit in ED set-shifting
performance. Ketamine-treated rats that received quetiapine
at a dose of 2.5 mg/kg also achieved the criterion during the
ED stage in fewer trials compared to the vehicle-treated
control group. Additionally, quetiapine administration (1.25
and 2.5 mg/kg) improved ED set-shifting in vehicle-treated
rats. Quetiapine did not affect any other discrimination
phase in either vehicle- or ketamine-treated rats.
The improved EDs performance after quetiapine adminis-
tration to ketamine-treated and control rats was accompanied
by the shortened duration of this discrimination phase
(vehicle–vehicle: 15.3±1.1, vehicle–quetiapine 1.25: 9.4±
1.2 and vehicle–quetiapine 2.5: 9.2±0.7; ketamine–vehicle:
23.5±1.5, ketamine–quetiapine 1.25: 14.2±1.5 and ket-
amine–quetiapine 2.5: 11.45±1.6; ANOVA interaction: F
(18,318)=1.87, P<0.05; data not shown).
Discussion
The present study reveals that the subchronic administration
of ketamine specifically impairs rats’ performance on the
ED stage of the attentional set-shifting task. Furthermore,
this ketamine-induced persistent cognitive inflexibility was
reversed by acute quetiapine and sertindole treatment.
Quetiapine also facilitated ED set-shifting in cognitively
unimpaired control animals.
The present demonstration of ketamine-induced ED set-
shifting impairment is in line with studies employing
repetitive dosing regimens of another NMDAR antagonist,
PCP. Indeed, PCP administered twice daily for 7 consecu-
tive days has been consistently demonstrated to impair rats’
performance in the ED stage of the ASST following a 10-
Fig. 2 Effects of sertindole on the deficit in the attentional set-shifting
task induced by repeated ketamine administration. Animals received
ten daily injections of ketamine. ASST was performed following the
14-day washout period. Sertindole was administered 120 min before
testing; N=6 rats per group. *** p<0.001 vs. the vehicle+vehicle-
treated group’s EDs performance,
### p<0.001 vs. the ketamine
+vehicle-treated group’s EDs performance
Fig. 3 Effects of quetiapine on
the deficit in the attentional
set-shifting task induced by re-
peated ketamine administration.
Animals received ten daily injec-
tionsofketamine,andthetestwas
carried out following the 14-day
washout period. Quetiapine was
administered 120 min before
testing; N=7–8 rats per group.
*** p<0.001 vs. the vehicle+
vehicle-treated group’s EDs per-
formance,
### p<0.001 vs. the
ketamine+vehicle-treated group’s
EDs performance
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2008; Goetghebeur and Dias 2009; McLean et al. 2008).
Additionally, Egerton et al. (2008) demonstrated selective
impairment of ED set-shifting occurring 72 h after the last
PCP administration following subchronic (5 days) and
chronic intermittent treatment regimes. In another study,
chronic (14-day) infusion of PCP via osmotic mini-pumps
to rats followed by a 7-day drug-free phase also produced
selective deficits in the ED stage (Pedersen et al. 2009). The
fact that similar results were obtained in neurodevelopmen-
tal schizophrenia models, i.e., early post-natal PCP admin-
istration (Broberg et al. 2008) or neonatal ventral
hippocampal lesions (Marquis et al. 2008), further supports
the utility of the ASST in preclinical schizophrenia
research.
In contrast to the present findings, using a similar schedule
of ketamine administration, Floresco et al. (2009)s h o w e d
drug-induced deficits in reversal learning during the instru-
mental and maze-based versions of the set-shifting task. This
discrepancy is not surprising in light of the available data. It
is known that NMDAR antagonist-induced impairments are
common in tasks specifically designed to assess reversal
learning ability at the level of changing stimulus–reward
contingencies (Abdul-Monim et al. 2007). Conversely, no
effect on reversal learning as assessed in the ASST procedure
has been demonstrated after either the repeated administra-
tion of PCP (Goetghebeur and Dias 2009; Rodefer et al.
2008; Egerton et al. 2005) or acute ketamine treatment
(Nikiforuk et al. 2010). As discussed by Floresco et al.
(2009), these discrepancies might be due to procedural
differences between these paradigms. In contrast to the
maze- and operant-based set-shifting protocols that involve
extended training, in the ASST, animals usually achieve CD
phase in six consecutive trials; this may prevent the
formation of a stable stimulus–reward association. Conse-
quently, reversal learning discrimination seems to be rela-
tively easy for animals, as indicated by the high basal level
of performance, and is therefore less prone to disruption.
However, the results of Floresco et al. (2009)a l s o
demonstrated that repeated ketamine administration im-
proved rats’ set-shifting performance due to the reduction
in perseverative errors. This pattern of responding was
similar to that previously noted in rats with inactivation of
the nucleus accumbens shell and interpreted as an inability to
learn the irrelevance of stimuli during the initial discrimina-
tion (Floresco et al. 2006a). Therefore, it is likely that the
current protocol is sensitive to different aspects of ketamine-
evoked set-shifting disruption as compared with the maze
and instrumental box protocols.
Alternatively, the differences in ketamine administration
protocols may contribute to these discrepancies. Ketamine
(30 mg/kg) was administered twice daily for 5 days in the
Floresco et al. study and once daily for 10 days in the
present experiments. However, Enomoto and Floresco
(2009) reported that 5 days of ketamine administration
was insufficient to induce PFC-dependent working memory
deficits; these occurred only after 10 days of drug
administration. Likewise, 5-day ketamine administration
did not affect ASST performance in the present study, while
the same drug administration protocol has been previously
shown to disrupt rats’ social behavior and latent inhibition
(Becker et al. 2003). Thus, it appears likely that to disrupt
mPFC-dependent functions, ketamine should be administered
for more than 5 days.
Finally, the potential limitation of the current experiments
is the fact that flexibility in shifting attentional set was
assessed only in one direction, i.e., from digging medium to
odor. However, an initial relevant dimension (odor or medium)
did not affect ED set-shifting (Nikiforuk et al. 2010), and it
cannot be excluded that ED performance of animals shifted
from medium to odor may be more susceptible to the
disrupting effects of ketamine.
Sertindole-induced inhibition of the ASST deficit agrees
with previous data demonstrating its efficacy in ameliorat-
ing ED deficits induced by either subchronic (Broberg et al.
2009; Goetghebeur and Dias 2009; Rodefer et al. 2008)o r
post-natal (Broberg et al. 2009) PCP administration in rats.
Similar beneficial effects of sertindole have been shown in
rats (Nikiforuk et al. 2010) and mice (Kos et al. 2011)
treated with ketamine acutely, confirming sertindole-
induced improvement of WCST performance in patients
with schizophrenia (Gallhofer et al. 2007). Thus, the
effectiveness of sertindole in reversing the subchronic
ketamine-induced attentional set-shifting deficit may sup-
port the predictive validity of the applied model in finding
novel compounds that purportedly improve cognitive
functioning.
The main finding of the current study is quetiapine-induced
facilitation of ED set-shifting; this is the first demonstration of
the effectiveness of this drug for modulating prefrontal
functions assessed in the ASST. The beneficial effect of
quetiapine on cognitive flexibility in ketamine-treated animals
may corroborate clinical data, as quetiapine has been demon-
strated to improve WCST performance in schizophrenic
patients (Kopala et al. 2006;P u r d o ne ta l .2001; Voruganti et
al. 2007). However, the lack of drug effects on this specific
aspect of executive skills has also been noted (Good et al.
2002; Keefe et al. 2007).
Although quetiapine’s effects on set-shifting have not yet
been addressed in preclinical studies, existing data suggest its
effectiveness in other cognitive domains. For example,
Tanibuchi et al. (2009) demonstrated that 2-week administra-
tion of quetiapine reversed the deficits caused by repeated
PCP administration on a novel object recognition task in
mice. Chronic treatment with quetiapine also counteracted
the impairment caused by acute PCP administration on rats’
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Additionally, acute administration of quetiapine restored
prepulse inhibition in PCP- and ketamine-treated rats
(Swerdlow et al. 1996; Swerdlow et al. 1998). In contrast
to its beneficial effects on preattentive information process-
ing, quetiapine treatment did not reverse PCP-induced
impairments on attention and impulsivity as assessed in the
5-choice serial reaction time task (Amitai and Markou 2009).
Nevertheless, the reported pro-cognitive action of quetiapine
was not restricted to schizophrenia-like states. Accordingly,
quetiapine treatment ameliorated learning and spatial mem-
ory impairments in rats exposed to enhanced single
prolonged stress, an animal model of post-traumatic stress
disorder (Wang etal. 2010). Quetiapine also alleviated spatial
working and reference memory deficits in a transgenic
mouse model of Alzheimer’sd i s e a s e( H ee ta l .2009).
Beneficial effects of quetiapine on cognitive functioning
were also noted in a cerebral ischemia model (Yan et al.
2007) and in a methamphetamine-induced neurotoxicity
model (He et al. 2006b). Correspondingly, the present
demonstration of quetiapine-induced facilitation of set-
shifting in cognitively unimpaired animals may predict its
efficacy in disorders other than schizophrenia that are also
characterized by disturbances in frontal-dependent cognitive
flexibility.
The cognitive benefits of quetiapine in the clinic have
been partially ascribed to its relatively low affinity for
dopamine D2 receptor together with fast dissociation from
these receptors and to the lack of affinity for M1 muscarinic
cholinergic receptors (Keefe et al. 2007; Kopala et al. 2006;
Riedel et al. 2007; Voruganti et al. 2007). As suggested by
Floresco et al. (2006b), D2 receptors may play an important
role in regulating set-shifting; the authors demonstrated that
the infusion of the D2 receptor antagonist eticlopride into
the rat mPFC disrupted set-shifting ability, as indicated by
the increase in perseverative errors (Floresco et al. 2006b).
Likewise, systemic administration of the D2 antagonist
sulpiride impaired attentional set-shifting in humans (Mehta
et al. 2004). Another line of research showed that
administration of the muscarinic antagonist scopolamine
also impaired rats’ performance on the ASST (Chen et al.
2004). Altogether, the unique receptor profile of quetiapine
may have an advantage over other antipsychotics.
In contrast to other novel generation antipsychotics (e.g.,
clozapine) that are characterized by a complex multi-
receptor profile, quetiapine displays marked affinity only
for 5-HT2A, D2, 5-HT1A, α1-adrenergic and α2-
adrenergic receptors (Richelson and Souder 2000). Some
data indicate that α1-adrenoreceptors might be involved in
the mechanism of action of quetiapine. Thus, quetiapine’s
effectiveness against PCP-induced cognitive deficits in
mice (Tanibuchi et al. 2009) and PCP-induced deficits in
prepulse inhibition (Bakshi and Geyer 1999) may have
resulted from the drug’s antagonism at α1-adrenoreceptors.
In contrast to this potential therapeutic implication of α1-
adrenergic antagonism, the results of Lapiz and Morilak
(2006) suggested that α1-receptor stimulation rather than
blockade may play a role in facilitating the ASST
responding. Thus, it remains questionable if the blockade
of α1-adrenergic receptors could improve prefrontal func-
tions specifically related to set-shifting capacity.
Recent data have indicated that the active metabolite of
quetiapine, N-desalkylquetiapine, may be involved in its
actions (Jensen et al. 2008). This compound was charac-
terized as a potent inhibitor of the noradrenaline reuptake
transporter (NET) (Jensen et al. 2008) and showed
relatively high affinity for the serotonin 7 (5-HT-7) receptor.
The pharmacological profile of N-desalkylquetiapine, al-
ready proposed to explain quetiapine’s antidepressant
actions, may also account for the drug's pro-cognitive
effects. Indeed, NET inhibitors may represent one of the
strategies destined to improve prefrontal functions in
schizophrenic patients (Apud and Weinberger 2007). In
our study, desipramine, a NET inhibitor, facilitated rats’
performance in ED set-shifting (Nikiforuk and Popik 2011).
Moreover, the selective blockade of 5-HT7 receptors has
been shown to be effective for ameliorating cognitive
deficits in an NMDAR-based animal model (McLean et
al. 2009) and for improving cognitive flexibility in rats (our
unpublished data). Therefore, one can assume that the
activities of N-desalkylquetiapine at the NET and/or 5-HT7
receptors may contribute to the pro-cognitive action of
quetiapine in the ASST.
It has been proposed that the ability of atypical antipsy-
chotic drugs to increase catecholamine levels in the prefrontal
cortex might underlie their potential pro-cognitive action.
Likewise, quetiapine has been demonstrated to increase
dopamine and noradrenaline levels in the rat mPFC (Ichikawa
et al. 2002;P i r ae ta l .2004;Y a m a m u r ae ta l .2009). However,
the lack of an effect of quetiapine on PFC dopamine release
was also noted (Denys et al. 2004). Because medications
enhancing frontal dopaminergic and noradrenergic neuro-
transmission were shown to facilitate ED set-shifting
(Nikiforuk et al. 2010; Nikiforuk and Popik 2011; Tunbridge
et al. 2004), the quetiapine-evoked increase in catecholamine
levels could account for its beneficial action in the ASST.
However, it should be noted that novel generation antipsy-
chotic drugs (i.e., risperidone and olanzapine) increased the
prefrontal dopamine level but had no effect on the set-
s h i f t i n gt a s k( R o d e f e re ta l .2008), suggesting that the mere
enhancement of dopamine release is insufficient to produce
facilitation of set-shifting. Furthermore, similarly to the actions
of sertindole but not risperidone (Morketal. 2009), quetiapine
enhances the cortical glutamate level (Yamamura et al. 2009).
The role of glutamatergic transmission in modulating
cognitive flexibility has previously been suggested (Nikiforuk
Psychopharmacology (2012) 220:65–74 71et al. 2011). Finally, elevation of the acetylcholine level in the
mPFC was also noted after quetiapine administration (Ichi-
kawa et al. 2002). Nevertheless, it remains equivocal whether
cholinergic transmission plays a critical role in the modula-
tion of attentional set-shifting because acetylcholine depletion
in the rat mPFC did not affect performance on that task
(McGaughy et al. 2008).
In summary, the present demonstration of the subchronic
ketamine-induced attentional set-shifting deficit reflects
clinically relevant aspects of cognitive dysfunction encoun-
tered in schizophrenic patients. Furthermore, the effective-
ness of sertindole in reversing ketamine-induced cognitive
inflexibility may support the predictive validity of the
applied model. Finally, the beneficial effects of quetiapine
on ASST performance may have therapeutic implications
for the treatment of schizophrenia and other disorders
associated with frontal-dependent cognitive impairments.
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